GLUE

Monte Rosa Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↑ 6/10
  • Value↓ 0/10
Monte Rosa Therapeutics sales and earnings growth
GLUE Growth
Good
  • Revenue Y/Y↓ -79.30%
  • EPS Y/Y↓ -1950.00%
  • FCF Y/Y↓ -164.49%
Monte Rosa Therapeutics gross and profit margin trends
GLUE Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -302.70%
  • ROIC 5Y↓ -34.63%
Monte Rosa Therapeutics net debt vs free cash flow
GLUE Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Monte Rosa Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks